Abbey Road Red announces ‘musical pharmaceutical’ platform MediMusic as its newest start-up

Abbey Road Red announces ‘musical pharmaceutical’ platform MediMusic as its newest start-up

10th November 2022

Abbey Road Red announces ‘musical pharmaceutical’ platform MediMusic as its newest start-up

We are thrilled to announce that MediMusic, a platform aiming to dispense music as medicine to help with symptoms of dementia, anxiety and pain, is the 18th start-up to join our music tech incubation programme, Abbey Road Red!

MediMusic is a groundbreaking medtech company which enables the prescription and provision of music as medicine to ease pain and anxiety.

It delivers music chosen using its proprietary algorithms and digital fingerprints, soon to be informed by machine learning, and already proven to ease stress in dementia patients.

Efficacy is tracked initially via heart rate, if the playlist is working the patients heart rate will lower, and if it doesn’t the platform will tweak the playlist. In the future other bio-markers will be added to the feedback loop.

MediMusic can be used in medical establishments including hospitals, care homes and dentist surgeries and it is anticipated that it could help reduce the cost of medication bills to these establishments by up to a quarter.

Incubation at Red

Incubation at Abbey Road Red will provide MediMusic with a development springboard to explore the effect of sound on physiology, relationships with key music and technology industry stakeholders, and advice from Red’s specialist mentor network.

Red will also help MediMusic refine and launch its next set of features including new bio-markers alongside heartrate, machine learning to fine-tune its dataset and improve its automated playlist curation, an enhanced set of proprietary data identifiers to describe the medical effects of songs, tackling the new area of pain reduction with music, and more.
“We identified music for wellness as an area of considerable importance at the 2019 Abbey Road Red Demo Day and have explored it resolutely since then. It’s incredibly exciting to take this to the next level with Gary and the team at MediMusic and explore music as a form of dispensed treatment, just as the sector is starting to show signs of maturity and genuine possibility. We look forward to helping MediMusic make its vision a reality which could positively impact millions of lives while relieving stress on health services.”

- Isabel Garvey, Managing Director, Abbey Road Studios,

“Studies have long shown a direct correlation between music and anxiety or stress reduction, as well as the potential for pain reduction. But implementing this research into effective dispensation in a medical context remains a big challenge. In MediMusic we believe we’ve found a music tech start-up which can succeed, supported by early traction in clinical trials, and a founder with anticipative vision who started this journey seven years ago. It’s a very special opportunity to play our part at Red.”

- Karim Fanous, Innovation Manager, Abbey Road Red

“We’re thrilled to have the support of Abbey Road Red and its music tech incubator programme to develop our revolutionary innovation of prescribing music as medicine. MediMusic has managed to digitally fingerprint the DNA of music so we can deliver the right songs as medicine to ease anxiety and stress. You could say it’s a musical pharmaceutical. Our initial clinical trials prove it has a very encouraging future in the treatment of patients. Using our technology, doctors, nurses and care home workers will be able to monitor the effect of the music in a clinical environment and see the benefits for themselves.

Using MediMusic could also reduce the use of drugs in treating anxiety and pain in patients by up to a quarter, thereby saving money for the NHS.

We passionately believe dispensing music as medicine is going to revolutionise the treatment of people in pain and stress, and we’re honoured that Abbey Road Red will help us on this journey."

- Gary Jones, founder of MediMusic

Related News